Want to see FATE full AI Analyst Report?
FATE Stock Chart & Stats
$2.57
-$0.11(-4.37%)
At close: 4:00 PM EDT
$2.57
-$0.11(-4.37%)
Day’s Range― - ―
52-Week Range$0.95 - $3.23
Previous CloseN/A
Volume1.04M
Average Volume (3M)1.43M
Market Cap
$222.87M
Enterprise Value$246.98M
Total Cash (Recent Filing)$153.77M
Total Debt (Recent Filing)$75.67M
Price to Earnings (P/E)―
Beta2.82
Next Earnings
Oct 29, 2026EPS Estimate
-0.27Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.05
Shares Outstanding119,820,510
10 Day Avg. Volume1,341,600
30 Day Avg. Volume1,433,660
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)0.56
Price to Sales (P/S)17.56
P/FCF Ratio-1.04
Enterprise Value/Market Cap1.11
Enterprise Value/Revenue38.05
Enterprise Value/Gross Profit-11.09
Enterprise Value/Ebitda-2.16
Forecast
1Y Price Target
$6.63Price Target Upside157.78% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering6
EPS Forecast (FY)-1.07
Revenue Forecast (FY)$5.61M
Bulls Say, Bears Say
Bulls Say
Off-the-shelf IPSC PlatformFate’s proprietary iPSC platform is designed to produce standardized, allogeneic immune-cell therapies that may be more broadly deployable than individualized approaches. If clinical efficacy is demonstrated, this model could support repeatable development across oncology and autoimmune indications.
Non-dilutive FT819 FundingThe $15 million grant provides non-dilutive support for a potentially registrational trial, reducing the immediate need to fund all development costs through equity. It also represents external validation of FT819 and improves the program’s ability to advance toward meaningful clinical milestones.
Regulatory And Clinical MomentumRMAT designation, FDA CMC pilot participation, and favorable early clinical observations create a stronger development framework for FT819. These factors may help Fate engage regulators and advance the lupus nephritis program more efficiently if later-stage results confirm the initial findings.
Bears Say
Volatile And Diminished RevenueFate lacks a stable commercial revenue base, and reported revenue has become both volatile and materially smaller than prior years. This makes operating performance dependent on collaboration-related receipts and other uneven sources, limiting visibility into sustainable business scale.
Persistent Operating LossesNegative gross profit and large operating losses show that Fate has not yet achieved an economically sustainable operating model. Even with some narrowing of losses, continued distance from break-even means future progress remains dependent on successful clinical development and additional funding.
Cash Burn And Shrinking Equity BasePersistent, sizable cash outflows consume financial resources while the shrinking equity base reduces flexibility. If the burn continues, Fate may need further financing to sustain development, creating ongoing dilution risk and potentially constraining capital allocation across its programs.
Fate Therapeutics News
FATE FAQ
What was Fate Therapeutics’s price range in the past 12 months?
Fate Therapeutics lowest stock price was $0.95 and its highest was $3.23 in the past 12 months.
What is Fate Therapeutics’s market cap?
Fate Therapeutics’s market cap is $222.87M.
When is Fate Therapeutics’s upcoming earnings report date?
Fate Therapeutics’s upcoming earnings report date is Oct 29, 2026 which is in 8 days.
How were Fate Therapeutics’s earnings last quarter?
Fate Therapeutics released its earnings results on Aug 13, 2026. The company reported -$0.25 earnings per share for the quarter, beating the consensus estimate of -$0.267 by $0.017.
Is Fate Therapeutics overvalued?
According to Wall Street analysts Fate Therapeutics’s price is currently Undervalued.
Does Fate Therapeutics pay dividends?
Fate Therapeutics does not currently pay dividends.
What is Fate Therapeutics’s EPS estimate?
Fate Therapeutics’s EPS estimate is -0.27.
How many shares outstanding does Fate Therapeutics have?
Fate Therapeutics has 119,820,510 shares outstanding.
What happened to Fate Therapeutics’s price movement after its last earnings report?
Fate Therapeutics reported an EPS of -$0.25 in its last earnings report, beating expectations of -$0.267. Following the earnings report the stock price went down -7.353%.
Which hedge fund is a major shareholder of Fate Therapeutics?
Currently, no hedge funds are holding shares in FATE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Fate Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$6.63 (157.78% Upside)
$6.63 (157.78% Upside)
Blogger Sentiment
Neutral
FATE Sentiment 50%
Sector Average 67%
Sector Average 67%
Hedge Fund Trend
Increased
By 70.4K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $202.7K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.9%
Last 30 Days ▲ 7.1%
Last 30 Days ▲ 7.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
33.76%
12-Months-Change
Fundamentals
Return on Equity
-65.08%
Trailing 12-Months
Asset Growth
-30.01%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Fate Therapeutics
Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to creating advanced, programmed cellular immunotherapies. These innovative treatments are designed to combat cancer and various immune disorders across the globe. A significant portion of its development pipeline concentrates on NK- and T-cell immuno-oncology programs. Key candidates include FT516, which targets acute myeloid leukemia (AML), B-cell lymphoma, and advanced solid tumors; FT596 for B-cell lymphoma and chronic lymphocytic leukemia; FT538, addressing AML and multiple myeloma; FT576, also focused on multiple myeloma; FT819, aimed at both hematologic malignancies and solid tumors; FT536, another program for solid tumors; and FT500, intended for advanced solid tumors. The company also actively engages in strategic collaborations to advance its research and development. It holds an agreement with Ono Pharmaceutical Co. Ltd. for the joint development and commercialization of two novel, "off-the-shelf" iPSC-derived CAR T-cell therapies. Furthermore, Fate Therapeutics maintains a research collaboration and licensing deal with Juno Therapeutics, Inc., focusing on identifying small molecule modulators that can enhance the therapeutic efficacy of genetically engineered T-cell immunotherapies. A separate collaboration and option agreement exists with Janssen Biotech, Inc. Established in 2007, Fate Therapeutics, Inc. is based in San Diego, California.
FATE Stock 12 Month Forecast
Average Price Target
$6.63
▲(157.78% Upside)
Technical Analysis
Ownership Overview
12.42% Insiders
12.29% Mutual Funds
1.13% Other Institutional Investors
68.47% Public Companies and
Individual Investors